PharmaCorp Rx Inc. is making waves on the TSX Venture Exchange with a notable uptick in its stock price.
PharmaCorp Rx Inc. (PCRX.V) is rising today, showing a gain of 1.02% to close at CA$0.49. This positive movement comes amidst significant corporate developments, including a recent public offering that has bolstered investor confidence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$96.35M
52W high
$0.58
52W low
$0.40
1W change
-5.77%
Beta
-4.27
Analyst Price Targets
Based on analyst covering PCRX
Wall Street analysts forecast PCRX stock price to rise 36.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+36.1% Upside
Current Price
C$0.49
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
70.6%
Annualized
90-Day Vol
61.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.52 | C$0.41 – C$0.66 |
| 60 trading days | C$0.55 | C$0.39 – C$0.78 |
| 90 trading days | C$0.59 | C$0.38 – C$0.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on PharmaCorp as it explores growth opportunities and raises capital, which could strengthen its market position.
PharmaCorp's Market Cap Reaches CA$96.35 Million
With a market cap of CA$96,349,128, PharmaCorp is set for further growth, but investors should remain cautious about its current financial performance.
Bull case
The recent C$11.5 million bought deal public offering shows strong market interest and gives PharmaCorp the capital it needs for expansion. This could lead to increased revenues and a larger market share.
Bear case
Despite the positive movement, PharmaCorp's profit margin is still negative, which suggests potential challenges in achieving profitability while pursuing growth.
Recent Developments Boosting Investor Confidence
PharmaCorp's announcement of a C$11.5 million bought deal public offering has been a key driver behind its stock's rise today. By issuing 22,549,200 units at CA$0.51 per unit, the company has secured essential funds for expansion and operational improvements. This move signals to investors that PharmaCorp is committed to scaling its operations and enhancing its market presence.
Financial Performance and Future Outlook
PharmaCorp has reported significant revenue growth in its recent financial results, with a 79.4% increase in revenue to $7.2 million for Q1 2026. However, despite these gains, the company still faces challenges with a profit margin of -0.0671. Investors should weigh the potential for continued growth against its current financial health. For more details on its financial performance, check out the latest reports on PharmaCorp's stock page.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
